These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 21057537)

  • 1. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
    Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
    Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells.
    Wang B; Li D; Rodriguez-Juarez R; Farfus A; Storozynsky Q; Malach M; Carpenter E; Filkowski J; Lykkesfeldt AE; Kovalchuk O
    BMC Cancer; 2018 Aug; 18(1):817. PubMed ID: 30103729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
    Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
    Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
    Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
    Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.
    Jiang Z; Guo J; Shen J; Jin M; Xie S; Wang L
    J Exp Clin Cancer Res; 2012 May; 31(1):42. PubMed ID: 22553917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells.
    Song RX; Chen Y; Zhang Z; Bao Y; Yue W; Wang JP; Fan P; Santen RJ
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):219-30. PubMed ID: 19815064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
    Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
    J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
    Long X; Fan M; Nephew KP
    Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
    Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
    Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.
    Liu L; Shen W; Zhu Z; Lin J; Fang Q; Ruan Y; Zhao H
    Biochem Biophys Res Commun; 2018 Apr; 498(3):559-565. PubMed ID: 29522716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.
    Morrison MM; Williams MM; Vaught DB; Hicks D; Lim J; McKernan C; Aurisicchio L; Ciliberto G; Simion C; Sweeney C; Cook RS
    Oncogene; 2016 Mar; 35(9):1143-52. PubMed ID: 26148232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells.
    Shaw LE; Sadler AJ; Pugazhendhi D; Darbre PD
    J Steroid Biochem Mol Biol; 2006 Apr; 99(1):19-32. PubMed ID: 16533599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
    Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
    J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
    JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
    Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells.
    Manavalan TT; Teng Y; Litchfield LM; Muluhngwi P; Al-Rayyan N; Klinge CM
    PLoS One; 2013; 8(4):e62334. PubMed ID: 23626803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
    Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
    Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.